At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 85 enrolled
Drug / intervention
inositol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIb Randomized Comparative Study of the Efficacy and Safety of Myo-inositol Versus Placebo in Smokers With Bronchial Dysplasia
In Brief
A Phase 2 clinical trial evaluating placebo and inositol for Non-small Cell Lung Cancer and Squamous Lung Dysplasia. Completed, enrolled 85 participants across 4 sites in 2 countries.
Detailed Summary
This randomized phase II trial is studying inositol to see how well it works compared with a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of inositol may prevent lung cancer. It is not yet known whether inositol is more effective than a placebo in preventing lung cancer in smokers with bronchial dysplasia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2008
First PostedNov 2008
Primary CompletionMay 2014
TodayJul 2026
First PostedNov 3, 2008
Enrollment StartNov 1, 2008
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 17.7 years ago
Interventions
placeboother
Given orally
inositoldrug
Given orally